Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
X LiE W Chan

Abstract

The purpose of this investigation was to evaluate the budget impact and cost-effectiveness of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection in Hong Kong. A decision analytic model was developed to compare short-term costs and health outcomes of patients with chronic HCV genotype 1 infection in Hong Kong who were treated with an interferon (INF)-based treatment (dual therapy of pegylated interferon and ribavirin) or DAA-based treatments (sofosbuvir or ledipasvir/sofosbuvir or ombitasvir/paritaprevir/ritonavir plus dasabuvir). Compared to INF-based treatment, DAA-based treatments yielded an incremental cost of $24,677-$31,171 per course while improving the rate of sustained virologic response (SVR) from 59-66% to 82.3-99.8%. The incremental cost-effective ratios of DAA-based treatments ranged from $9724 to $29,189 per treatment success, which were all below the cost-effectiveness threshold of local GDP per capita ($42,423 in 2015). Introducing DAAs resulted in a 126.1% ($383.7 million) budget increase on HCV infection management over 5 years. A 50% change in DAA medication costs reflected a change in the incremental budget from $55.2 to $712.3 million. DAA-based treatments are cost-effecti...Continue Reading

References

Apr 15, 2006·International Journal of Medical Sciences·Stephen L Chen, Timothy R Morgan
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 1, 2011·The New England Journal of Medicine·Bruce R BaconUNKNOWN HCV RESPOND-2 Investigators
Jun 22, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Francisco M AverhoffDeborah Holtzman
Dec 4, 2012·Best Practice & Research. Clinical Gastroenterology·Heather LewisGraham Foster
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Adriaan J van der MeerHarry L A Janssen
Jan 3, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Homie RazaviRitesh Kumar
Nov 5, 2013·World Journal of Gastroenterology : WJG·Rui Tato Marinho, David Pires Barreira
Jan 17, 2014·AIDS Patient Care and STDs·Lynn E TaylorKenneth H Mayer
Jan 21, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sean D SullivanWen-Yi Shau
Apr 15, 2014·The New England Journal of Medicine·Fred PoordadBarry Bernstein
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
Apr 25, 2014·BMC Research Notes·Joanne LaFleurRichard E Nelson
Aug 3, 2014·Journal of Hepatology·Erin GowerHomie Razavi
Aug 15, 2014·JAMA : the Journal of the American Medical Association·Anita KohliShyam Kottilil
Mar 17, 2015·Annals of Internal Medicine·Mehdi NajafzadehNiteesh K Choudhry
Mar 18, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David B ReinJohn W Ward
Aug 21, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Cherrishe Bickerstaff
Sep 4, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Vicente Gimeno-BallesterRamón San Miguel
Nov 3, 2015·Current Opinion in Infectious Diseases·Prarthana Thiagarajan, Stephen D Ryder
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael S LyonsKenneth E Sherman

❮ Previous
Next ❯

Software Mentioned

Excel

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.